| Haber: |
Haber Kaynağı: Çeşitli Haber Siteleri
STAT+: Pharmalittle: GSK to pay up to $3.3 billion for Affinivax; Senate bill tries to avoid another Aduhelm controversy
Looking to bolster its vaccines business with new technology, GSK is buying Affinivax in a transaction worth up to $3.3 billion.
https://www.statnews.com/pharmalot/2022/05/31/covid19-vaccines-gsk-aduhelm-counterfeit-hiv/?utm_campaign=rss
|
